Absci entered its new drug into Phase I trials in half the time and for many millions of dollars less than it would have cost without AI.

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

The firm's methods - using real human tissue samples in the lab - give drug developers a more accurate picture of how their ...

CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...

In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, W ...

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is ...

Dimerix and its kidney drug is on track but with results of its phase III trial not due for years, a few more twists and turns are likely.

Moderna (NasdaqGS:MRNA) initiated the dosing for its innovative mRNA-4106 cancer therapy in a Phase 1 trial, signaling ongoing advancements in their oncology pipeline. However, the company's stock ...

Researchers at the Paul Scherrer Institute PSI have developed an AI that could open up a new, cost-effective approach to ...

ASX-listed pharmaceutical companies were among the worst performers across the ASX 200 on Monday after US President Donald ...

Trump’s drug pricing order sparks global pharma sell-off as industry warns of stifled innovation and revenue loss in key US ...